TRCT
PLRX icon

Tower Research Capital (TRC)’s Pliant Therapeutics PLRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,315
Closed -$4.18K – 5544
2026
Q1 		$4.18K Buy
+3,315
New +$4.18K ﹤0.01% 4226
2025
Q4 		– Sell
-20,749
Closed -$30.7K – 5483
2025
Q3 		$30.7K Sell
20,749
-2,561
-11% -$3.91K ﹤0.01% 2916
2025
Q2 		$27K Buy
23,310
+9,794
+72% +$13.8K ﹤0.01% 3483
2025
Q1 		$18.2K Buy
13,516
+11,871
+722% +$72.1K ﹤0.01% 3056
2024
Q4 		$21.7K Sell
1,645
-84
-5% -$1.15K ﹤0.01% 3125
2024
Q3 		$19.4K Sell
1,729
-5,960
-78% -$74.6K ﹤0.01% 3253
2024
Q2 		$82.7K Buy
7,689
+6,979
+983% +$90K ﹤0.01% 2717
2024
Q1 		$10.6K Sell
710
-13,733
-95% -$227K ﹤0.01% 3682
2023
Q4 		$262K Buy
14,443
+5,273
+58% +$80.2K ﹤0.01% 1881
2023
Q3 		$159K Buy
9,170
+6,721
+274% +$117K 0.01% 1606
2023
Q2 		$44.4K Buy
2,449
+1,790
+272% +$42.4K ﹤0.01% 2670
2023
Q1 		$17K Sell
659
-976
-60% -$27.8K ﹤0.01% 3644
2022
Q4 		$32K Sell
1,635
-3,777
-70% -$79K ﹤0.01% 2693
2022
Q3 		$113K Buy
5,412
+2,289
+73% +$43.8K ﹤0.01% 2462
2022
Q2 		$25K Buy
3,123
+853
+38% +$5.46K ﹤0.01% 3569
2022
Q1 		$16K Buy
2,270
+640
+39% +$6.53K ﹤0.01% 3765
2021
Q4 		$22K Buy
1,630
+923
+131% +$14.7K ﹤0.01% 3569
2021
Q3 		$11K Sell
707
-884
-56% -$18.8K ﹤0.01% 4246
2021
Q2 		$46K Buy
1,591
+34
+2% +$1.06K ﹤0.01% 3091
2021
Q1 		$61K Buy
1,557
+305
+24% +$9.9K ﹤0.01% 2959
2020
Q4 		$29K Sell
1,252
-3,173
-72% -$79.6K ﹤0.01% 3601
2020
Q3 		$100K Buy
+4,425
New +$111K ﹤0.01% 3146

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Tower Research Capital (TRC)'s PLRX Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of Pliant Therapeutics (PLRX) in Q2 2026, closing a stake of 3,315 shares — an estimated $4.18K sold.

Tower Research Capital (TRC) first reported a position in PLRX in Q3 2020 and held it in 22 quarters. The position peaked at $262K in Q4 2023. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

  • Tower Research Capital (TRC) reported no remaining Pliant Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 3,315 Pliant Therapeutics shares in Q2 2026, an estimated $4.18K.
  • Tower Research Capital (TRC) first reported a position in Pliant Therapeutics in Q3 2020 and held it in 22 quarters.
  • Tower Research Capital (TRC)'s Pliant Therapeutics position peaked at $262K in Q4 2023.
  • 86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.